Cargando…

NK Cell-Based Immunotherapy in Cancer Metastasis

Metastasis represents the leading cause of cancer-related death mainly owing to the limited efficacy of current anticancer therapies on advanced malignancies. Although immunotherapy is rendering promising results in the treatment of cancer, many adverse events and factors hampering therapeutic effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzo-Herrero, Seila, López-Soto, Alejandro, Sordo-Bahamonde, Christian, Gonzalez-Rodriguez, Ana P, Vitale, Massimo, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357056/ https://www.ncbi.nlm.nih.gov/pubmed/30597841 http://dx.doi.org/10.3390/cancers11010029

Ejemplares similares

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
por: Cantoni, Claudia, et al.
Publicado: (2016)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
por: Acebes-Huerta, Andrea, et al.
Publicado: (2014)

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis
por: Roato, Ilaria, et al.
Publicado: (2019)

Molecular Bases for the Regulation of NKG2D Ligands in Cancer
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy
por: Gutiérrez-Hoya, Adriana, et al.
Publicado: (2021)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
por: Cepeda-Piorno, Francisco-Javier, et al.
Publicado: (2022)

NK cell-based immunotherapy for treating cancer: will it be promising?
por: Cho, Duck, et al.
Publicado: (2011)

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
por: Kang, Synat, et al.
Publicado: (2021)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

NK Receptors: Tools for a Polyvalent Cell Family
por: Sivori, Simona, et al.
Publicado: (2014)

miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020)

Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
por: Sivori, Simona, et al.
Publicado: (2020)

NK Cell-Based Immunotherapy in Renal Cell Carcinoma
por: Terrén, Iñigo, et al.
Publicado: (2020)

Technical advances in NK cell-based cellular immunotherapy
por: Fang, Fang, et al.
Publicado: (2019)

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
por: Pan, Changqing, et al.
Publicado: (2021)

Prospects for NK-based immunotherapy of chronic HBV infection
por: Jin, Xiaomeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hc1tovvj95ffd0ih723cm13v8d